Trials / Unknown
UnknownNCT06066255
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
REINFORCED PROPHYLAXIS OF GVH IN ELDERLY PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: USE OF A LOW DOSE OF POST-ALLOGRAFT ANTI-LYMPHOCYTIC SERUM
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 60 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to evaluate the efficacy of GVH prophylaxis reinforced by low-dose Thymoglobulin administered at the end of aplasia after haploidentical allogeneic transplantation. Patients will receive a single infusion of Thymoglobulin at a dose of 1 mg/kg between 48h and 72h after emergence from aplasia, and will be followed for 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thymoglobulin Injectable Product | single intravenous injection of thymoglobulin |
Timeline
- Start date
- 2024-03-31
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2023-10-04
- Last updated
- 2024-02-20
Source: ClinicalTrials.gov record NCT06066255. Inclusion in this directory is not an endorsement.